Zimmer Biomet (NYSE:ZBH) Price Target Raised to $122.00 at BTIG Research

Zimmer Biomet (NYSE:ZBH) had its price objective boosted by BTIG Research from $118.00 to $122.00 in a research note published on Monday morning, MarketBeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

Other analysts have also recently issued reports about the company. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price target for the company. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a report on Thursday, September 18th. Finally, Raymond James Financial increased their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $113.16.

Zimmer Biomet Stock Up 0.4%

NYSE ZBH opened at $95.13 on Monday. The business has a fifty day moving average price of $101.36 and a 200 day moving average price of $98.03. Zimmer Biomet has a one year low of $89.22 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The company has a market cap of $18.85 billion, a P/E ratio of 23.15, a P/E/G ratio of 2.18 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Garde Capital Inc. acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $30,000. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $35,000. Finally, Cullen Frost Bankers Inc. increased its holdings in shares of Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.